Please wait...


The issue of drugs and medicine is not as severe as it is with its approval.

Medicines and drugs cannot be taken and used by patients unless they have been approved by the FDA.

Food and Drug Administration

However, to seriously and quickly consider and get rid of this problem the Food and Drug Administration or FDA has developed a few methods.

In the case of those drugs and medicines that promises and offers far greater chances of being cured from a specific disease when taken, the FDA will issue a fast approval by means of any of the following:

  • Priority Review
  • Breakthrough Therapy
  • Fast Track
  • Accelerated Approval

The FDA provides Priority Review only for those drugs and medicines which offer room for significant improvement once administered to the patient. These medicines are considered to improve the patient’s condition. Furthermore, the FDA has devised many methods to understand the efficiency of the product or the medicine.

The drugs which are approved under Priority Review of the FDA should:

  • Have evidence for the drugs’ or medicines’ effectiveness to improve the condition, improve the diagnosis or improve the healing process once administered to the patient.
  • Either eliminate or reduce the disease or condition for which the drug was made.
  • Have solid evidence for its safety.
  • Have a documented evidence that the drug will improve the patients’ health under serious circumstances.
Only recently, at the beginning of February, FDA gave Priority Review and approvals to various drugs.

Only recently, at the beginning of February, FDA gave Priority Review and approvals to various drugs. Among the large list of drugs to be approved under the FDA’s Priority Review, the drug Erleada was also present.

This drug basically works for those patients who suffer from prostate cancer which has not yet spread to other parts of the body but continues to grow despite the treatment.

Erleada was tested vigorously by the FDA, and the endpoints of the drug were thoroughly considered. The organization tested and found out how long the drug takes to spread through the body or made a note of the time of death after beginning with the treatment. Other than this, the organization also looked into the matter of safety and efficiency of the drug.

Apart from this, there were multiple other oncology agents who were offered an approval under Priority Review. Here is a list of some of the drugs:

  • Dabrafenib (Tafinlar, Novartis) – which is a BRAF inhibitor.
  • Daratumumab (Darzalex; Janssen, Genmab) – which is a monoclonal antibody.
  • Iobenguane I 131 (Azedra, Progenics Pharmaceuticals) – It is a transporter for norepinephrine reuptake.
  • Osimertinib (Tagrisso, AstraZeneca) – This is an inhibitor of epidermal growth factor receptor tyrosine kinase.
  • Pembrolizumab (Keytruda, Merck) – It offers anti-PD1 therapy.

All of the above-mentioned drugs and medicines have been tested as per the standards of FDA and have been approved only after showing the expected results of using the drug or medicine.

Deep Lush

Chemistry, Intimacy, Porn - This is Deep Lush
Chemistry, Intimacy, Porn – This is Deep Lush

Deep Lush series being online video content is not required to have FDA approvals. This might be the best thing about adults-only series available online these days. As soon as the production and post-production process is done you can enjoy the very best of what authors prepared.

With Deep Lush it’s the way of having an intercourse. Authors wanted to show that it can be intimate, performers can have chemistry while doing it and everything still can be very provocative.

Did they succeed? You need to see it yourself.

The reason for FDA’s incorporation of Priority Review and other methods of quick approval of the drugs was because of the fact that these drugs could improve the quality of life for the patients and will reduce the time for treatment significantly.


“French society of
radiation oncologists”

The SFRO was an organisation that was brought on board more than a decade ago for purposes of promoting the teaching of radiation oncology in France. Ever since its inception, the organisation has grown extensively. It now features as many as 120 members from across France. The members are afforded an opportunity to learn about radiation oncology and to acquire in-depth knowledge on how to administer treatment through the use of the various techniques that exist today. Every year, two nation courses are organised to enable the members to learn some important information about cancer and how to treat it through the use of radiation oncology. All the members receive an invitation whenever new courses are introduced. The goal is to make sure that all members are at the same level in as far as knowledge is concerned. In case of new information, the members are kept up to date to ensure that they are acquainted with any advancements in the treatment of the disease.

Brief History Of The Society

“Brief History Of The Society”

The society was formed in 2002 and is thus 15 years old. Membership was and remains free to all individuals who have prospects of joining the society. The organisation works hand in hand with other organisations that are involved in the fight against cancer. From 2002, its sister organisation the SJFRO has been working with the SFRO to promote training in cancer treatment. In its nearly two decades of existence, the organisation has worked tirelessly to make sure that its members are given adequate and accurate information on cancer. The society has successfully managed to stimulate research in cancer treatment among its members. Not shocking, a number of amazing results have been registered by the society since the time it was brought on board.

Teaching Information

“Following information for
the courses”

Every year, the society invites its members following the addition of new courses. This is aimed at making sure that all the members are exposed to the same nature of information. There are many teaching courses that the society offers to its members. The teaching information and courses are taught by highly qualified professors whose credentials are backed by immense experience in the treatment of cancer using radiation oncology. All the courses that are provided by the society are directly related to cancer itself (without special reference to any type of cancer). The society has a well organised teaching structure. It features four semesters of radiation oncology, two semesters awarded to medical oncology and another two semesters awarded to radiation oncology and its related fields.

Learning Radiation Therapy

“Learning Radiation Therapy”

The organisation is directly involved in the dispensation of various courses to help medical students become fully equipped with knowledge and skills related to radiation oncology. All the individuals who sign up for membership with the society are actually full time medical doctors who have already obtained a medical studies degree. It takes around six years for medical doctors to complete their studies in France. Once they have successfully completed their studies. The study time frame at the society’s learning centres normally lasts five years. This is often referred to as the residency time.

“Radiation oncology residency”

Therefore, students who enrol for radiation oncology are said to enrol for radiation oncology residency. During the course of the five years, the society receives a wide range of courses which are taught one after another or alongside each other. The major courses that the society receives are cellular and molecular biology, pharmacology, genetics, medical imaging, cell death, immunity, pathology, stem cells, oncogenesis, epidemiology, chemotherapy and angiogenesis. There are other mandatory courses which the members are required to attend. These include radiophysics, radiation therapy and radiobiology courses among others.

From the above, it is clear that the SFRO is certainly one of the most important societies in France. Its contribution to the research, treatment of cancer patients and training of medical experts is certainly remarkable.


The Société Française Radiation Oncology is an organisation that is concerned with the provision of information about radiation oncology.

Copyright by Société Française 2017. All rights reserved.